# Gan & Lee Insulin Glargine Target Type (2) Evaluating Research

> **NCT03371108** · PHASE3 · COMPLETED · sponsor: **Gan and Lee Pharmaceuticals, USA** · enrollment: 567 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **BIOLOGICAL:** Gan & Lee Insulin Glargine Injection
- **BIOLOGICAL:** Lantus®

## Key facts

- **NCT ID:** NCT03371108
- **Lead sponsor:** Gan and Lee Pharmaceuticals, USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-31
- **Primary completion:** 2019-04-17
- **Final completion:** 2019-04-17
- **Target enrollment:** 567 (ACTUAL)
- **Last updated:** 2022-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03371108

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03371108, "Gan & Lee Insulin Glargine Target Type (2) Evaluating Research". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03371108. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*